
MIST Stock Forecast & Price Target
MIST Analyst Ratings
Bulls say
Milestone Pharmaceuticals Inc. has shown a promising outlook due to the successful outcomes of the ReVeRA study, which highlighted statistically significant improvements in patient-reported symptom relief and PSVT conversion rates, indicating strong clinical efficacy for etripamil. The company is further positioned to capitalize on this momentum with an FDA-agreed streamlined Phase 3 program for atrial fibrillation, suggesting a pathway to expedited regulatory approval and an effective commercial launch. Additionally, Milestone's planned presence at major cardiovascular conferences in 2025 is likely to enhance public engagement and support, potentially driving substantial shareholder value in the near-term.
Bears say
Milestone Pharmaceuticals faces a negative outlook primarily due to the competitive landscape in the treatment of paroxysmal supraventricular tachycardia (PSVT) and atrial fibrillation with rapid ventricular rate (AFib-RVR), where existing oral therapies like beta-blockers may offer delayed relief. The company’s reliance on etripamil could be challenged by the low adoption rates of catheter ablation among eligible patients, limiting the market for medication-based management, which is essential for those who do not seek invasive procedures. Additionally, despite the reported efficacy of etripamil in achieving rapid heart rate reduction, the underappreciation of its market potential and serious patient needs suggests that the current valuation of MIST shares might not reflect an optimistic growth trajectory.
This aggregate rating is based on analysts' research of Milestone Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
MIST Analyst Forecast & Price Prediction
Start investing in MIST
Order type
Buy in
Order amount
Est. shares
0 shares